- Home
- CDMO
as 12-18-2024 10:33am EST
Avid Bioservices Inc is a clinical-stage biopharmaceutical company focused on the development and Current Good Manufacturing Practices (CGMP) of biopharmaceutical products derived from mammalian cell culture. Its business is organized into one reportable operating segment which is contract manufacturing and development services segment. Its services include clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing and regulatory submissions support. The company also provides a variety of process development services including cell line development, upstream and downstream development and optimization, analytical method development, testing and characterization.
| Founded: | 1981 | Country: | United States |
| Employees: | N/A | City: | TUSTIN |
| Market Cap: | 784.1M | IPO Year: | N/A |
| Target Price: | $13.63 | AVG Volume (30 days): | 1.3M |
| Analyst Decision: | Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.39 | EPS Growth: | N/A |
| 52 Week Low/High: | $5.65 - $12.48 | Next Earning Date: | 12-10-2024 |
| Revenue: | $150,445,000 | Revenue Growth: | 6.75% |
| Revenue Growth (this year): | 19.05% | Revenue Growth (next year): | 20.88% |
Stock Insider Trading Activity of Avid Bioservices Inc. (CDMO)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Kwietniak Matthew R. | CDMO | Chief Commercial Officer | Oct 11 '24 | Sell | $10.15 | 119 | $1,207.86 | 25,407 | |
| Richieri Richard A. | CDMO | Chief Operations Officer | Oct 9 '24 | Sell | $10.05 | 2,232 | $22,431.60 | 37,704 | |
| Kwietniak Matthew R. | CDMO | Chief Commercial Officer | Oct 9 '24 | Sell | $10.05 | 982 | $9,869.10 | 25,407 | |
| Green Nicholas Stewart | CDMO | President & CEO | Oct 9 '24 | Sell | $10.05 | 17,173 | $172,588.65 | 226,653 |
Latest Avid Bioservices Inc. News
CDMO Breaking Stock News: Dive into CDMO Ticker-Specific Updates for Smart Investing
Associated Press Finance
7 days ago
Avid Bioservices: Fiscal Q2 Earnings Snapshot
GlobeNewswire
8 days ago
Avid Bioservices Reports Financial Results for Second Quarter Ended October 31, 2024
MT Newswires
14 days ago
Stephens Downgrades Avid Bioservices to Equalweight, Price Target is $12.50
Insider Monkey
a month ago
Avid Bioservices, Inc. (CDMO): A Bull Case Theory
TipRanks
a month ago
Avid Bioservices to be Acquired in $1.1 Billion Deal
Pharmaceutical Technology
a month ago
GHO and Ampersand Capital to acquire Avid Bioservices
The Wall Street Journal
a month ago
Avid Bioservices to Go Private in $1.1 Billion Deal
GlobeNewswire
a month ago
Avid Bioservices to be Acquired by GHO Capital Partners and Ampersand Capital Partners in $1.1 Billion Transaction
Compare CDMO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CDMO Avid Bioservices Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.